Sustained-release fampridine for symptomatic treatment of multiple sclerosis.

Sustained-release fampridine for symptomatic treatment of multiple sclerosis. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Sustained-release fampridine for symptomatic treatment of multiple sclerosis. Abstract Text:

OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical trials, and adverse effects of sustained-release (SR) fampridine in patients with multiple sclerosis (MS). DATA SOURCES: An English-language human data search was done using PubMed/MEDLINE (1966-August 2008) to retrieve relevant material using the search terms fampridine-SR, 4-aminopyridine, and multiple sclerosis. References of selected articles and information from the drug developer were used to further identify pertinent trials. STUDY SELECTION AND DATA EXTRACTION: Article selection was based primarily on studies that evaluated the pharmacokinetics, safety, and efficacy of fampridine-SR in patients with MS. Relevant meeting abstracts were also included as part of the analysis. DATA SYNTHESIS: Fampridine-SR is a sustained-release, orally administered potassium-channel blocker acting in the central nervous system to enhance conduction in demyelinated axons. Several small trials have evaluated the safety and efficacy of fampridine-SR in patients with MS to improve their walking ability. Data from a recent large Phase 3 trial indicated that walking speed improved in 42.9% of patients with MS who were treated with fampridine-SR compared with 9.3% of those who received placebo (p < 0.001). Treatment-related adverse events associated with the use of fampridine-SR include dizziness, insomnia, nausea, and paresthesia. More severe adverse events, such as seizure, have occurred in patients receiving doses higher than those currently recommended. CONCLUSIONS: Positive results from 2 Phase 3 clinical trials have put fampridine-SR on the path toward approval as a medication for improving walking speed and lower extremity strength in patients with MS.

Sustained-release fampridine for symptomatic treatment of multiple sclerosis. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Sustained-release fampridine for symptomatic treatment of multiple sclerosis. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: The Annals of pharmacotherapy

VOLUME: 42

Page Numbers: 1458-65

Journal Abbreviation:

ISSN: 1542-6270

DAY: 9

MONTH: 09

YEAR: 2008

Sustained-release fampridine for symptomatic treatment of multiple sclerosis. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9203131

Sustained-release fampridine for symptomatic treatment of multiple sclerosis. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Sustained-release fampridine for symptomatic treatment of multiple sclerosis. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Sustained-release fampridine for symptomatic treatment of multiple sclerosis.

AFFILIATION: Pharmacy Practice Resident, Skaggs School of Pharmacy, The University of Montana; Community Medical Center, Missoula, MT; now, Assistant Professor, College of Pharmacy, Nursing, and Allied Health, North Dakota State University, Fargo, ND.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Ann Pharmacother

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Sustained-release fampridine for symptomatic treatment of multiple sclerosis Related Publications

• Anal comedos and pruritus ani.
• Autosensitization dermatitis; report of five cases and protocol of an experiment.
• CAPILLARY ANEURYSMS OF THE SKIN.
• Capillary aneurysms.
• Detection of fibrin(ogen) degradation products by a latex clumping method.
• Eyelid tumors.
• Liquid nitrogen in the treatment of skin diseases.
• Scabicidal Drugs: An Experimental Study.
• Sustained-release fampridine for symptomatic treatment of multiple sclerosis.
• The effect of parenteral nutrition with different lipid emulsions on platelets.
• The latex flocculation inhibition test for the detection of fibrin(ogen) degradation products.
• Thrombotest method for the control of anticoagulant therapy.
• Traumatic Epithelial Cysts.